APA

Jazayeri-Tehrani S. A., Rezayat S. M., Mansouri S., Qorbani M., Alavian S. M., Daneshi-Maskooni M. & Hosseinzadeh-Attar M. (2019). Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. : Nutrition & metabolism.

Chicago

Jazayeri-Tehrani Seyed Ali, Rezayat Seyed Mahdi, Mansouri Siavash, Qorbani Mostafa, Alavian Seyed Moayed, Daneshi-Maskooni Milad and Hosseinzadeh-Attar Mohammad-Javad. 2019. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. : Nutrition & metabolism.

Harvard

Jazayeri-Tehrani S. A., Rezayat S. M., Mansouri S., Qorbani M., Alavian S. M., Daneshi-Maskooni M. and Hosseinzadeh-Attar M. (2019). Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. : Nutrition & metabolism.

MLA

Jazayeri-Tehrani Seyed Ali, Rezayat Seyed Mahdi, Mansouri Siavash, Qorbani Mostafa, Alavian Seyed Moayed, Daneshi-Maskooni Milad and Hosseinzadeh-Attar Mohammad-Javad. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. : Nutrition & metabolism. 2019.